TEL AVIV, Israel & ZURICH & NEW YORK – SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN), an organization specializing in superior private telemedicine options, has introduced that the TELE-ACS scientific trial outcomes shall be showcased on the American Faculty of Cardiology’s twenty fourth Annual Scientific Session & Expo (ACC 24). The trial, a collaboration with Imperial Faculty London, examines the effectiveness of distant cardiovascular affected person evaluation post-acute coronary syndrome utilizing SHL’s SmartHeart® expertise.

The presentation, scheduled for April 6, 2024, will reveal the total findings of the TELE-ACS trial, a examine that might mark a major development in telemedicine for cardiovascular care. The trial centered on high-risk sufferers following an acute coronary syndrome and utilized SHL’s SmartHeart® 12-lead ECG expertise for at-home monitoring.

Erez Nachtomy, CEO of SHL Telemedicine, expressed pleasure within the trial’s choice for ACC 24, recognizing it as a testomony to the diligent efforts of the workforce at Imperial Faculty London. The outcomes, that are at present embargoed, shall be shared with the worldwide cardiology neighborhood throughout the convention.

SHL Telemedicine, listed on each the SIX Swiss Change and the Nasdaq Inventory Change, gives telemedicine methods and medical name middle companies, concentrating on cardiovascular and associated ailments. The corporate provides its companies and gadgets to subscribers by way of telephonic and web communication applied sciences.

The announcement relies on a press launch assertion.

InvestingPro Insights

As SHL Telemedicine Ltd. (NASDAQ: SHLTN) prepares to disclose the TELE-ACS scientific trial outcomes, traders and stakeholders are intently observing the corporate’s monetary well being and market efficiency. In accordance with the newest knowledge from InvestingPro, SHL Telemedicine holds a market capitalization of 110.19 million USD, indicating its dimension and significance within the telemedicine trade. Regardless of current challenges, because the inventory has fared poorly over the past month with a 16.55% drop, SHL Telemedicine’s liquid property exceed its short-term obligations, which can present some monetary stability for the corporate.

InvestingPro Ideas recommend that SHL Telemedicine is buying and selling close to its 52-week low and operates with a average stage of debt, which may current a shopping for alternative for traders who imagine within the firm’s long-term prospects. Notably, the agency has not been worthwhile over the past twelve months, and it doesn’t pay a dividend to shareholders, indicating that potential traders ought to have a tolerance for threat and a give attention to development potential.

For these fascinated with a deeper evaluation, InvestingPro+ provides further tips about SHL Telemedicine, and with the present particular New Yr sale, subscriptions are actually accessible at as much as 50% off. To additional improve this provide, use coupon code SFY24 to get a further 10% off a 2-year InvestingPro+ subscription, or SFY241 to get a further 10% off a 1-year InvestingPro+ subscription.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.